Geneva, Switzerland, July 1, 2021 – AMAL Therapeutics announced today that the latest findings of its in vivo research team is on line on the Frontiers in Immunology website. Altogether, the results presented highlight the potential of combining stimulator of interferon gene agonists (STINGa) with a therapeutic protein vaccine for cancer treatment.